Intuitive Surgical

Intuitive Surgical's growth has slowed from post-pandemic highs as new competitors like Medtronic and Johnson & Johnson enter the surgical-robotics market, though da Vinci placements rose to 468 in Q2 2026. Surgeries using da Vinci increased 16% year over year, and roughly 75% of revenue now comes from services and instruments, creating annuity-like income. Valuation multiples are below five-year averages after a roughly 40% drawdown, making the stock potentially attractive for investors who can tolerate high volatility. » Plus sur finance.yahoo.com

TCW's Q2 2026 investor letter highlights Intuitive Surgical, noting solid quarterly results, revenue and Da Vinci procedure growth above estimates, but weaker system placements in China and Japan. ISRG repurchased 2.3M shares for $1.1B in 1Q26 and management raised 2026 guidance, yet shares have lagged amid negative sentiment toward medtech and high-growth multiples. TCW expects further penetration from the early rollout of Da Vinci 5 and cites a 20-year lead and strong competitive moat, remaining constructive on the stock. » Plus sur finance.yahoo.com

Intuitive Surgical's stock has fallen about 33% in 2026 amid concerns over competition from China and potential AI disruption, yet its forward P/E near 35 is well below the five-year average. The company has an installed base of over 12,000 systems across 70+ countries and recurring revenue from instruments and services makes up roughly 75% of sales. Fund managers and most analysts still expect mid-teens revenue growth and view the lower share price as a buying opportunity for long-term, risk-tolerant investors. » Plus sur finance.yahoo.com